Overview Financials News + Filings IR Vault Key Docs Charts Transactions Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
Appointed director
CC transcript
|
|
BRISTOL MYERS SQUIBB CO (BMY)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/08/2019 |
8-K
| Asset disposition, Entered into an accelerated share repurchase agreement|
Docs:
|
"Consent of KPMG LLP, independent registered public accounting firm of Celgene Corporation",
"The historical audited consolidated financial statements and financial statement schedule of Celgene Corporation as of December 31, 2018 and 2017 and for each of the years in the three-year period ended December 31, 2018, the notes related thereto and the related reports of KPMG LLP, Celgene’s independent registered public accounting firm",
"Unaudited pro forma condensed combined financial information of Bristol-Myers Squibb Company giving effect to the acquisition of Celgene Corporation, which includes the unaudited pro forma condensed combined balance sheet as of December 31, 2018, the unaudited pro forma condensed combined statement of earnings for the year ended December 31, 2018, and the notes related thereto" |
|
| 04/28/2009 |
8-K
| Form 8-K - Current report |
| 05/12/2005 |
8-K
| Form 8-K - Current report |
|
|